Loading…
Company announces significant efficacy in early-stage trial.
Moderna, Inc. (Nasdaq: MRNA) disclosed that its experimental cancer vaccine demonstrated a 150% increase in efficacy metrics during an early-stage clinical trial. The announcement was made following the completion of the trial's primary endpoint assessment.
The trial evaluated the vaccine's performance in a specific cancer type, with results showing a notable improvement over standard treatments. Moderna did not provide a direct comparator for this increase.
As of the latest available data, Moderna has a free float of 372,347,352 shares.
This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.